Name | Number of supported studies | Average coverage | |
---|---|---|---|
basal cell | 15 studies | 34% ± 11% | |
ciliated cell | 13 studies | 28% ± 7% | |
oligodendrocyte | 12 studies | 39% ± 18% | |
epithelial cell | 10 studies | 42% ± 11% | |
macrophage | 10 studies | 21% ± 6% | |
fibroblast | 10 studies | 27% ± 15% | |
astrocyte | 9 studies | 36% ± 16% | |
non-classical monocyte | 8 studies | 24% ± 6% | |
pericyte | 8 studies | 20% ± 4% | |
type I pneumocyte | 7 studies | 25% ± 9% | |
classical monocyte | 7 studies | 22% ± 5% | |
enterocyte | 7 studies | 47% ± 20% | |
club cell | 6 studies | 24% ± 8% | |
epithelial cell of proximal tubule | 6 studies | 26% ± 4% | |
kidney loop of Henle epithelial cell | 6 studies | 44% ± 15% | |
ionocyte | 5 studies | 49% ± 10% | |
respiratory goblet cell | 5 studies | 33% ± 5% | |
conventional dendritic cell | 5 studies | 25% ± 8% | |
smooth muscle cell | 5 studies | 23% ± 4% | |
secretory cell | 4 studies | 31% ± 12% | |
abnormal cell | 4 studies | 35% ± 13% | |
connective tissue cell | 4 studies | 21% ± 3% | |
myofibroblast cell | 3 studies | 22% ± 7% | |
progenitor cell | 3 studies | 29% ± 9% | |
endothelial cell | 3 studies | 20% ± 3% | |
monocyte | 3 studies | 21% ± 5% | |
dendritic cell | 3 studies | 29% ± 2% | |
oligodendrocyte precursor cell | 3 studies | 33% ± 12% | |
goblet cell | 3 studies | 20% ± 4% | |
glial cell | 3 studies | 29% ± 8% | |
transit amplifying cell | 3 studies | 18% ± 2% | |
keratinocyte | 3 studies | 38% ± 19% | |
hepatocyte | 3 studies | 33% ± 10% | |
CD4-positive, alpha-beta T cell | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 4405.45 | 89 / 89 | 100% | 92.82 | 899 / 901 |
skin | 100% | 4401.92 | 1808 / 1809 | 99% | 97.63 | 469 / 472 |
liver | 100% | 4292.29 | 226 / 226 | 99% | 214.46 | 403 / 406 |
thymus | 99% | 2266.40 | 646 / 653 | 99% | 58.94 | 596 / 605 |
bladder | 100% | 2229.29 | 21 / 21 | 97% | 99.36 | 490 / 504 |
prostate | 99% | 2186.43 | 243 / 245 | 98% | 70.09 | 491 / 502 |
uterus | 97% | 1588.16 | 165 / 170 | 100% | 109.13 | 457 / 459 |
intestine | 100% | 3428.44 | 965 / 966 | 95% | 55.95 | 501 / 527 |
stomach | 99% | 3374.16 | 357 / 359 | 93% | 46.47 | 266 / 286 |
lung | 95% | 1940.30 | 550 / 578 | 97% | 184.31 | 1122 / 1155 |
esophagus | 99% | 3956.44 | 1435 / 1445 | 93% | 89.96 | 170 / 183 |
adrenal gland | 100% | 4027.63 | 258 / 258 | 92% | 68.32 | 211 / 230 |
brain | 100% | 4643.95 | 2641 / 2642 | 87% | 92.56 | 614 / 705 |
ovary | 91% | 1177.29 | 164 / 180 | 94% | 38.32 | 404 / 430 |
pancreas | 79% | 796.28 | 259 / 328 | 97% | 57.36 | 173 / 178 |
breast | 96% | 1338.07 | 440 / 459 | 78% | 37.04 | 874 / 1118 |
tonsil | 0% | 0 | 0 / 0 | 100% | 138.38 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 40.20 | 1 / 1 |
spleen | 99% | 1804.90 | 239 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 1849.86 | 1314 / 1335 | 0% | 0 | 0 / 0 |
adipose | 96% | 1411.08 | 1160 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 58.82 | 75 / 80 |
lymph node | 0% | 0 | 0 / 0 | 86% | 44.01 | 25 / 29 |
heart | 74% | 773.55 | 640 / 861 | 0% | 0 | 0 / 0 |
muscle | 65% | 690.09 | 519 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 38% | 410.54 | 355 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0019371 | Biological process | cyclooxygenase pathway |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0008211 | Biological process | glucocorticoid metabolic process |
GO_0030855 | Biological process | epithelial cell differentiation |
GO_0042373 | Biological process | vitamin K metabolic process |
GO_0070062 | Cellular component | extracellular exosome |
GO_1903561 | Cellular component | extracellular vesicle |
GO_0005829 | Cellular component | cytosol |
GO_0004090 | Molecular function | carbonyl reductase (NADPH) activity |
GO_0047021 | Molecular function | 15-hydroxyprostaglandin dehydrogenase (NADP+) activity |
GO_0008106 | Molecular function | alcohol dehydrogenase (NADP+) activity |
GO_0050221 | Molecular function | prostaglandin E2 9-reductase activity |
GO_0016655 | Molecular function | oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor |
GO_0160163 | Molecular function | S-nitrosoglutathione reductase (NADPH) activity |
GO_0016616 | Molecular function | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor |
GO_0047020 | Molecular function | 15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity |
Gene name | CBR1 |
Protein name | Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (15-hydroxyprostaglandin dehydrogenase [NADP(+)]) (EC 1.1.1.196, EC 1.1.1.197) (20-beta-hydroxysteroid dehydrogenase) (Alcohol dehydrogenase [NAD(P)+] CBR1) (EC 1.1.1.71) (NADPH-dependent carbonyl reductase 1) (Prostaglandin 9-ketoreductase) (PG-9-KR) (Prostaglandin-E(2) 9-reductase) (EC 1.1.1.189) (Short chain dehydrogenase/reductase family 21C member 1) Carbonyl reductase 1 |
Synonyms | SDR21C1 CBR CRN |
Description | FUNCTION: NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol . Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione . In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue . . |
Accessions | E9PQ63 A8MTM1 ENST00000530908.5 [P16152-2] ENST00000290349.11 [P16152-1] ENST00000399191.3 ENST00000439427.2 P16152 |